MCID: HPT019
MIFTS: 60

Hepatic Encephalopathy

Categories: Liver diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hepatic Encephalopathy

MalaCards integrated aliases for Hepatic Encephalopathy:

Name: Hepatic Encephalopathy 12 75 53 37 55 15 72
Portal-Systemic Encephalopathy 12
Encephalopathy, Hepatic 53
Hepatoencephalopathy 53

Classifications:



External Ids:

Disease Ontology 12 DOID:13413
KEGG 37 H01506
ICD9CM 35 572.2
MeSH 44 D006501
NCIt 50 C79596
SNOMED-CT 68 13920009
ICD10 33 K72
UMLS 72 C0019151

Summaries for Hepatic Encephalopathy

NIH Rare Diseases : 53 Hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. It is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded. Signs and symptoms may be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. They may include personality or mood changes, intellectual impairment, abnormal movements, a depressed level of consciousness, and other symptoms. There are several theories regarding the exact cause, but development of the condition is probably at least partially due to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. Treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis.

MalaCards based summary : Hepatic Encephalopathy, also known as portal-systemic encephalopathy, is related to hepatic coma and alcoholic liver cirrhosis. An important gene associated with Hepatic Encephalopathy is TSPO (Translocator Protein), and among its related pathways/superpathways are Circadian entrainment and Immune response IL-23 signaling pathway. The drugs Metformin and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood.

KEGG : 37
Hepatic encephalopathy (HE) is a brain dysfunction caused by liver insufficiency or portal systemic shunting. HE most commonly occurs in decompensated liver cirrhosis and incorporates a spectrum of manifestations that ranges from mild cognitive impairment to coma. Although its pathogenesis is not entirely understood, one of the main factors is thought to be ammonia. Apart from hyperammonemia, various other pathogenic mechanisms, such as the gamma-aminobutyric acid (GABA) theory, the benzodiazepine theory, the manganese theory, and the theory of oxidative/nitrosative stress, have been implicated in the development of HE. The pharmacological treatments that are currently used in clinical practice are directed toward reducing the production and absorption of gut-derived ammonia.

Wikipedia : 75 Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may... more...

Related Diseases for Hepatic Encephalopathy

Diseases related to Hepatic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 393)
# Related Disease Score Top Affiliating Genes
1 hepatic coma 33.2 TSPO GPT F2 ALB
2 alcoholic liver cirrhosis 33.0 SLC17A5 F2 ALB
3 liver cirrhosis 32.6 SLC17A5 GPT F2 ALB
4 acute liver failure 31.5 TSPO SLC17A5 GPT GC F2 ALB
5 alcoholic hepatitis 31.5 TNF SLC17A5 IL6 GPT F2 ALB
6 portal hypertension 31.1 TNF GPT F2 ALB
7 peritonitis 30.9 TNF IL6 F2 ALB
8 meningitis 30.7 TNF IL6 ALB
9 end stage renal failure 30.7 TNF IL6 ALB
10 non-a-e hepatitis 30.6 F2 ALB
11 fatty liver disease 30.5 TNF SLC17A5 IL6
12 schistosomiasis 30.5 TNF F2 ALB
13 eclampsia 30.3 TNF F2 ALB
14 brain edema 30.3 SLC25A13 SLC1A2 IL6 GLUL ALB
15 peripheral nervous system disease 30.3 TNF IL6 ALB
16 wilson disease 30.2 GPT F2 ALB
17 appendicitis 30.2 TNF IL6 ALB
18 gastroenteritis 30.2 TNF IL6 ALB
19 viral hepatitis 30.2 TNF SLC17A5 GPT F2 ALB
20 meningoencephalitis 30.1 SLC17A5 IL6 ALB
21 acquired immunodeficiency syndrome 30.1 TNF IL6 ALB
22 proteasome-associated autoinflammatory syndrome 1 30.1 TNF IL6 ALB
23 intestinal disease 30.1 TNF IL6 ALB
24 infantile liver failure syndrome 1 30.1 SLC17A5 GPT F2 ALB
25 cerebrovascular disease 30.1 TSPO TNF IL6 F2
26 paracetamol poisoning 30.0 GC F2
27 cholecystitis 29.9 GPT F2 ALB
28 mood disorder 29.9 MAOB MAOA IL6
29 cholestasis 29.8 SLC25A13 GPT F2
30 gastrointestinal system disease 29.8 TNF IL6 F2 ALB
31 hepatitis e 29.8 TNF GPT F2 ALB
32 liver disease 29.7 TNF SLC25A13 SLC17A5 IL6 GPT F2
33 hepatitis 29.7 TNF SLC17A5 GPT F2
34 protein-energy malnutrition 29.6 TNF IL6 GPT ALB
35 hepatitis a 29.6 TNF GPT F2 ALB
36 central nervous system disease 29.5 TNF MAOB IL6 GC
37 kwashiorkor 29.5 SLC17A5 GPT F2 ALB
38 bilirubin metabolic disorder 29.5 SLC17A5 GPT F2 ALB
39 hepatitis b 29.4 TNF SLC17A5 GPT F2 ALB
40 cholangitis 29.4 TNF IL6 GPT F2 ALB
41 heart disease 29.0 TNF S100B IL6 F2 ALB
42 nervous system disease 28.7 TNF S100B MAOB IL6 GC ALB
43 psychotic disorder 28.6 S100B NOS1 MAOB
44 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.6
45 combined oxidative phosphorylation deficiency 1 12.1
46 hepatorenal syndrome 11.5
47 congenital extrahepatic portosystemic shunt 11.5
48 encephalopathy 11.4
49 3-hydroxyacyl-coa dehydrogenase deficiency 11.3
50 hepatic veno-occlusive disease 11.2

Comorbidity relations with Hepatic Encephalopathy via Phenotypic Disease Network (PDN): (show all 24)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Decubitus Ulcer Deficiency Anemia
Encephalopathy Esophageal Varix
Heart Disease Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Liver Disease
Neutropenia Portal Hypertension
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Urea Cycle Disorder

Graphical network of the top 20 diseases related to Hepatic Encephalopathy:



Diseases related to Hepatic Encephalopathy

Symptoms & Phenotypes for Hepatic Encephalopathy

MGI Mouse Phenotypes related to Hepatic Encephalopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 F2 GLS GLUL IL6 MAOA MAOB
2 homeostasis/metabolism MP:0005376 10.17 ALB F2 GC GLUL IL6 MAOA
3 mortality/aging MP:0010768 9.9 ALB F2 GLS GLUL IL6 NOS1
4 liver/biliary system MP:0005370 9.8 ALB GLUL IL6 NOS1 SLC25A13 TNF
5 nervous system MP:0003631 9.65 F2 GLUL IL6 MAOA MAOB NOS1
6 normal MP:0002873 9.23 ALB F2 GLS GLUL NOS1 S100B

Drugs & Therapeutics for Hepatic Encephalopathy

Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
5
Magnesium oxide Approved Phase 4 1309-48-4 14792
6
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
7
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
8
Cefoxitin Approved Phase 4 35607-66-0 441199
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
11
Azithromycin Approved Phase 4 83905-01-5 447043 55185
12
Vancomycin Approved Phase 4 1404-90-6 441141 14969
13
Insulin Aspart Approved Phase 4 116094-23-6 16132418
14
Promethazine Approved, Investigational Phase 4 60-87-7 4927
15
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
16
Histamine Approved, Investigational Phase 4 51-45-6 774
17
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
18
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
19
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
20
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
23
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
24
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
25
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
26
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
27
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
28
Azathioprine Approved Phase 4 446-86-6 2265
29
Atorvastatin Approved Phase 4 134523-00-5 60823
30
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
31
Tranexamic Acid Approved Phase 4 1197-18-8 5526
32
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
33
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
34
Tolvaptan Approved Phase 4 150683-30-0 216237
35
Ethanol Approved Phase 4 64-17-5 702
36
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
37
Lorazepam Approved Phase 4 846-49-1 3958
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
39
Isoleucine Approved, Investigational, Nutraceutical Phase 4 443-79-8, 73-32-5 6306
40
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
41 Hypoglycemic Agents Phase 4
42 arginine Phase 4
43 Adjuvants, Anesthesia Phase 4
44 Anesthetics, General Phase 4
45 Anesthetics, Intravenous Phase 4
46 Amoxicillin-Potassium Clavulanate Combination Phase 4
47 Antitubercular Agents Phase 4
48 Excitatory Amino Acid Agonists Phase 4
49 Excitatory Amino Acids Phase 4
50 Pharmaceutical Solutions Phase 4

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
2 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
3 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
4 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study Unknown status NCT03077217 Phase 4 Rifaximin
5 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
6 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
7 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
8 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
9 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
10 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
11 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
12 A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Rifaximin and Lactulose
13 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
14 The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
15 Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Completed NCT01559519 Phase 4 Albumin
16 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
17 High-fiber High-fiber Diet and Branched Chain Aminoacids. Impact on Nutritional Status and Complications in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
18 Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study Completed NCT00955500 Phase 4
19 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
20 Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
21 LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial Completed NCT01847651 Phase 4 LOLA or placebo
22 A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
23 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
24 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
25 Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
26 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
27 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
28 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
29 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
30 Ramelteon for Treatment of Insomnia in Cirrhosis Completed NCT03091738 Phase 4 Ramelteon Pill
31 Study of the Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis Completed NCT01686698 Phase 4
32 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
33 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
34 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
36 Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
37 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4 Human albumin;Placebo
38 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Recruiting NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
39 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
40 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
41 Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial Recruiting NCT04028323 Phase 4 Terlipressin;Octreotide
42 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
43 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
44 Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology Terminated NCT01824589 Phase 4
45 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
46 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
47 Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
48 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Unknown status NCT00364689 Phase 3 Rifaximin alone, Rifaximin combined with Lactulose
49 A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy Unknown status NCT02464124 Phase 2, Phase 3 Nitazoxanide;Lactulose
50 Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. Unknown status NCT01798329 Phase 3

Search NIH Clinical Center for Hepatic Encephalopathy

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Kanamycin Sulfate
Lactulose
Lactulose
Neomycin
NEOMYCIN SO4 PWDR
Rifaximin

Genetic Tests for Hepatic Encephalopathy

Anatomical Context for Hepatic Encephalopathy

MalaCards organs/tissues related to Hepatic Encephalopathy:

41
Liver, Brain, Testes, Cortex, Colon, Kidney, Cerebellum

Publications for Hepatic Encephalopathy

Articles related to Hepatic Encephalopathy:

(show top 50) (show all 7738)
# Title Authors PMID Year
1
Conventional diet therapy for hyperammonemia is risky in the treatment of hepatic encephalopathy associated with citrin deficiency. 9 38
20118603 2010
2
Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone. 9 38
20373079 2010
3
[A simple scoring system to evaluate the severity of acute-on-chronic liver failure in hepatitis B]. 9 38
20193566 2009
4
[Analysis of prognostic factors for patients with acute-on-chronic liver failure]. 9 38
19719920 2009
5
Retrospective study of the clinical profile and prognostic indicators in patients of alcoholic liver disease admitted to a tertiary care teaching hospital in Western Nepal. 9 38
19636178 2009
6
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 9 38
19663083 2009
7
Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. 9 38
19267864 2009
8
Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy. 9 38
19082698 2009
9
Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. 9 38
19175915 2009
10
In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model. 9 38
18941414 2008
11
Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy. 9 38
18773287 2008
12
[Clinical outcomes and predictive factors of spontaneous survival in patients with fulminant hepatitis A]. 9 38
19119242 2008
13
[Natural history of primary biliary cirrhosis]. 9 38
18928750 2008
14
Gc-globulin in liver disease. 9 38
19232164 2008
15
Which is the best way to analyze the efficacy of albumin dialysis in hepatic encephalopathy? 9 38
18666248 2008
16
Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters. 9 38
18344887 2008
17
Prognostic factors for chronic severe hepatitis and construction of a prognostic model. 9 38
18234637 2008
18
Acute liver failure in Lithuania. 9 38
18695350 2008
19
Aquaporin-4 in hepatic encephalopathy. 9 38
17879149 2007
20
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. 9 38
17975845 2007
21
[Analysis of survival rate and risk factors of liver retransplantation]. 9 38
18005577 2007
22
Liver support systems. 9 38
17464150 2007
23
Drug insight: the role of albumin in the management of chronic liver disease. 9 38
17203088 2007
24
Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. 9 38
16941171 2006
25
Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. 9 38
16550382 2006
26
[Observation on hybrid bioartificial liver support systems in treating chronic severe hepatitis: a study of 60 cases]. 9 38
16556417 2006
27
Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. 9 38
16534681 2006
28
Role of endogenous benzodiazepine ligands and their GABA-A--associated receptors in hepatic encephalopathy. 9 38
16382352 2005
29
Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. 9 38
16382342 2005
30
[Preliminary study on the effects of an artificial liver support system in the treatment of medicamentous liver insufficiency]. 9 38
16313729 2005
31
[Analysis of prognostic factors of and to establish a predictive model for patients with chronic severe hepatitis]. 9 38
16248942 2005
32
Successful treatment of an adult with Amanita phalloides-induced fulminant liver failure with molecular adsorbent recirculating system (MARS). 9 38
16200238 2005
33
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. 9 38
16123966 2005
34
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. 9 38
15985009 2005
35
Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. 9 38
15861019 2005
36
[Analysis on prognostic factors of liver failure in children]. 9 38
16201463 2005
37
The impact of total plasma exchange on early allograft dysfunction. 9 38
15621091 2004
38
Clinical and laboratory features of spontaneous bacterial peritonitis. 9 38
15626058 2004
39
Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. 9 38
15246207 2004
40
Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. 9 38
14678008 2004
41
Benzodiazepine receptor antagonists for hepatic encephalopathy. 9 38
15106178 2004
42
Clinical significance and prediction factors of gastric varices in patients with hepatocellular carcinoma. 9 38
14571795 2003
43
Low serum total thyroxine and free triiodothyronine in patients with hepatic encephalopathy due to non-alcoholic cirrhosis. 9 38
12811678 2003
44
Renal impairment after spontaneous bacterial peritonitis: incidence and prognosis. 9 38
12677269 2003
45
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. 9 38
12639207 2003
46
Discriminant function for prognostic indexes and probability of death in chronic severe hepatitis B. 9 38
14564632 2003
47
Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. 9 38
12950957 2003
48
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients. 9 38
12395325 2002
49
Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes. 9 38
12143047 2002
50
Glutamine synthetase in brain: effect of ammonia. 9 38
12020613 2002

Variations for Hepatic Encephalopathy

Expression for Hepatic Encephalopathy

LifeMap Discovery
Genes differentially expressed in tissues of Hepatic Encephalopathy patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PSPH phosphoserine phosphatase Brain - 4.35 0.000
Search GEO for disease gene expression data for Hepatic Encephalopathy.

Pathways for Hepatic Encephalopathy

Pathways related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 SLC1A2 NOS1 MAOB MAOA GLUL GLS
2
Show member pathways
12.38 TNF NOS1 IL6 F2
3
Show member pathways
12.04 TNF IL6 F2 ALB
4
Show member pathways
11.85 TNF IL6 F2
5 11.85 TSPO S100B ALB
6 11.81 TNF NOS1 IL6
7 11.77 TNF MAOA IL6
8
Show member pathways
11.76 TNF SLC1A2 NOS1
9 11.59 MAOA GLUL GLS
10
Show member pathways
11.3 NOS1 MAOB MAOA
11
Show member pathways
11.07 TNF NOS1 MAOA
12
Show member pathways
10.94 GPT GLUL GLS
13 10.86 TNF IL6
14
Show member pathways
10.69 MAOB MAOA
15 10.69 GPT GLUL GLS
16 10.64 MAOB MAOA
17
Show member pathways
10.59 MAOB MAOA
18
Show member pathways
10.34 SLC1A2 GLUL
19
Show member pathways
10.34 NOS1 GPT GLUL GLS

GO Terms for Hepatic Encephalopathy

Cellular components related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 TNF S100B IL6 GPT GC F2
2 mitochondrion GO:0005739 9.17 TSPO SLC25A13 NOS1 MAOB MAOA GLUL

Biological processes related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.78 TSPO TNF S100B IL6
2 positive regulation of chemokine production GO:0032722 9.49 TNF IL6
3 glutamate secretion GO:0014047 9.46 SLC1A2 GLS
4 L-glutamate transmembrane transport GO:0015813 9.43 SLC25A13 SLC1A2
5 response to glucocorticoid GO:0051384 9.43 TNF S100B IL6
6 neurotransmitter catabolic process GO:0042135 9.4 MAOB MAOA
7 negative regulation of lipid storage GO:0010888 9.37 TNF IL6
8 dopamine catabolic process GO:0042420 9.32 MAOB MAOA
9 positive regulation of neuroinflammatory response GO:0150078 9.16 TNF IL6
10 cellular amino acid biosynthetic process GO:0008652 9.13 GPT GLUL GLS
11 positive regulation of glial cell proliferation GO:0060252 8.8 TSPO TNF IL6

Molecular functions related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-glutamate transmembrane transporter activity GO:0005313 8.96 SLC25A13 SLC1A2
2 primary amine oxidase activity GO:0008131 8.62 MAOB MAOA

Sources for Hepatic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....